ImmunityBio Inc (NASDAQ:IBRX)’s traded shares stood at 8.65 million during the last session, with the company’s beta value hitting 0.01. At the close of trading, the stock’s price was $3.24, to imply a decrease of -2.99% or -$0.1 in intraday trading. The IBRX share’s 52-week high remains $7.63, putting it -135.49% down since that peak but still an impressive 43.52% since price per share fell to its 52-week low of $1.83.
Analysts have given a consensus recommendation of Sell for ImmunityBio Inc (IBRX), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 1 analyst(s) give IBRX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 0 recommend it as a Buy.
ImmunityBio Inc (NASDAQ:IBRX) trade information
After registering a -2.99% downside in the last session, ImmunityBio Inc (IBRX) has traded red over the past five days. The 5-day price performance for the stock is 10.58%, and 37.29% over 30 days. With these gigs, the year-to-date price performance is 26.56%.
The extremes give us $6 and $6 for target low and target high price respectively. As such, IBRX has been trading -85.19% off suggested target high and -85.19% from its likely low.
IBRX Dividends
ImmunityBio Inc has its next earnings report out in July. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is BLACKROCK INC. with 11.42 million shares, or about 1.6629% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $72.19 million.
